Clicky

Depression

What We Tell Patients about Depression, and What They Say They Have Been Told

And, yes—we often hear anecdotes concerning patients who tell their current clinician some version of, ‘My psychiatrist said I have a chemical imbalance . . .’ But where is the evidence that this is what patients were actually told? Who has contacted the patient’s psychiatrist, or reviewed his/her case notes, to see if that was […]

What We Tell Patients about Depression, and What They Say They Have Been Told Read More »

US marks slowest population growth since the Depression

WASHINGTON – U.S. population growth has slowed to the lowest rate since the Great Depression, the Census Bureau said, as Americans continued their march to the South and West and one-time engines of growth, New York and California, lost political influence. Altogether, the U.S. population rose to 331,449,281 last year, the Census Bureau said Monday,

US marks slowest population growth since the Depression Read More »

Novel Combination Therapy for Major Depressive Disorder Gets Priority Review

The Food and Drug Administration (FDA) has granted Priority Review to AXS-05 (dextromethorphan-bupropion; Axsome Therapeutics) for the treatment of major depressive disorder (MDD). AXS-05 consists of dextromethorphan, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor that serves to increase the bioavailability of dextromethorphan. The NDA is supported by data from

Novel Combination Therapy for Major Depressive Disorder Gets Priority Review Read More »

Verily, LivaNova kick off study of nerve stimulation for treatment-resistant depression

With the launch of a new study, Verily and LivaNova are hoping to take the “treatment-resistant” out of treatment-resistant depression. About a year after teaming up to form a research collaboration, the partners have officially kicked off their Uncover study, which will collect a range of daily mental and physical health data from patients who

Verily, LivaNova kick off study of nerve stimulation for treatment-resistant depression Read More »

FDA clears three-minute depression treatment with Brainsway’s Theta Burst | 2021-04-26

Depression treatment still isn’t “once and done,” but the time needed to reduce symptoms continues to drop for patients using electromagnetic stimulation. Brainsway Ltd.’s Theta Burst brings treatment times down to just three minutes with its FDA 510(k) clearance. The therapy uses Jerusalem-based Brainsway’s Deep Transcranial Magnetic Stimulation (dTMS) system, previously approved for a 20-minute

FDA clears three-minute depression treatment with Brainsway’s Theta Burst | 2021-04-26 Read More »